PL EN


Preferences help
enabled [disable] Abstract
Number of results
2020 | 74 | 191-197
Article title

Ideal coronary stent: development, characteristics, and vessel size impact

Content
Title variants
PL
Wzorcowy stent wieńcowy: rozwój, charakterystyka i wpływ średnicy naczynia
Languages of publication
EN PL
Abstracts
EN
The invasive treatment of coronary artery disease (CAD) has been a well-established therapeutic method for many years. Bare-metal stents (BMS), followed by subsequent generations of drug-eluting stent (DES) implantation in a narrowed coronary artery is the most effective treatment, especially in patients with acute coronary syndromes. Restenosis and stent thrombosis are the most important complications of this method. The long-term results of percutaneous coronary intervention (PCI) depend not only on the type of the implanted stent, operator skills, but also on the clinical characteristics of the patient, including the size of the treated vessel. In the era of DES, small vessels (< 3 mm) proved to be one of the most important factors significantly worsening the clinical outcomes of PCI. Among the most important features of the stents available on the market, i.e. the type of drug released, the type of polymer and the strut thickness, the latter seems to be crucial, particularly for the treatment of small vessels.
PL
Inwazyjne leczenie choroby wieńcowej od wielu lat stanowi ugruntowaną metodę terapeutyczną. Implantacja najpierw stentów metalowych (BMS), a następnie kolejnych generacji stentów uwalniających leki (DES) w miejscu zwężonej tętnicy wieńcowej jest najskuteczniejszą metodą leczenia, zwłaszcza u pacjentów z ostrymi zespołami wieńcowymi. Restenoza i zakrzepica w stencie to główne powikłania tej metody. Wyniki odległe przezskórnej interwencji wieńcowej (PCI) zależą nie tylko od rodzaju implantowanego stentu, umiejętności operatora, lecz także od charakterystyki klinicznej pacjenta, w tym rozmiaru stentowanego naczynia. W erze stentów DES małe naczynia (< 3 mm) okazały się jednym z najważniejszych czynników w istotny sposób pogarszających rezultaty kliniczne PCI. Spośród najistotniejszych cech dostępnych na rynku stentów, tj. rodzaju uwalnianego leku, typu polimeru oraz grubości przęseł, ta ostatnia wydaje się kluczowa, szczególnie w przypadku leczenia małych naczyń.
Discipline
Publisher

Year
Issue
74
Pages
191-197
Physical description
Contributors
author
  • 2nd Department of Cardiology, Faculty of Medical in Zabrze, Medical University of Silesia, Katowice, Poland
  • 2nd Department of Cardiology, Faculty of Medical in Zabrze, Medical University of Silesia, Katowice, Poland
author
  • 2nd Department of Cardiology, Faculty of Medical in Zabrze, Medical University of Silesia, Katowice, Poland
  • 2nd Department of Cardiology, Faculty of Medical in Zabrze, Medical University of Silesia, Katowice, Poland
  • 2nd Department of Cardiology, Faculty of Medical in Zabrze, Medical University of Silesia, Katowice, Poland, damian.kawecki@sum.edu.pl
References
  • 1. Kardiologia Interwencyjna. Red. nauk. G. Brzezińska-Rajszys, M. Dąbrowski, W. Rużyłło, A. Witkowski. Wydawnictwo Lekarskie PZWL. Warszawa 2009, s. 27–31.
  • 2. Moscucci M. Grossman & Baim’s Cardiac Catheterization, Angiography, and Intervention. 7th Edition. Lippincott Williams & Wilkins. Philadelphia 2006, s. 76–79.
  • 3. Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral, and Structural Heart Disease. Ed. D. Mukherjee, E. Bates, M. Roffi, D. Moliterno. CRC Press. Texas 2010, s. 173–194.
  • 4. Cardiac catheterization and percutaneous interventions. Ed. I. Kay, M. Sabate, M. Costa. Taylor & Francis Group. London 2004, s. 16–44, doi. org/10.3109/9780203494837.
  • 5. Carrié D., Elbaz M., Andrieu M., Cantié P., Fourcade J., Puel J. Ten-year clinical and angiographic follow-up of coronary wallstent. Am. J. Cardiol. 2000; 85(1): 95–98, doi:10.1016/S0002-9149(99)00613-X.
  • 6. Butany J., Carmichael K., Leong S.W., Collins M.J. Coronary artery stents: identification and evaluation. J. Clin. Pathol. 2005; 58(8): 795–804, doi: 10.1136/jcp.2004.024174.
  • 7. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., Detre K., Veltri L., Ricci D., Nobuyoshi M. et al. A randomised comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 1994; 331(8): 496–501, doi: 10.1056/NEJM199408253310802.
  • 8. Serruyes P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., Emanuelsson H., Marco J., Legrand V., Materne P. et. al. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. On behalf of the Benestent Study Group. N. Engl. J. Med. 1994; 331(8): 489–495, doi: 10.1056/NEJM199408253310801.
  • 9. Moussa I., Di Mario C., Di Francesco L., Reimers B., Blengino S., Colombo A. Subacute stent thrombosis and the anticoagulation controversy: Changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Am. J. Cardiol. 1996; 78(3A): 13–17, doi: 10.1016/S0002-9149(96)00486-9.
  • 10. Serruys P.W., Di Mario C. Who was thrombogenic: The stent or the doctor? Circulation 1995; 91(6): 1891–1893, doi: 10.1161/01.CIR.91.6.1891.
  • 11. Hoffmann R., Jansen C., Konig A., Haager P.K., Kerckhoff G., vom Dahl J., Klauss V., Hanrath P., Mudra H. Stent design related neointimal tissue proliferation in human coronary arteries; an intravascular ultrasound study. Eur. Heart J. 2001; 22(21): 2007–2014, doi: 10.1053/euhj.2001.2606.
  • 12. Handbook of coronary stents. Ed. P.W. Serruys, B. Rensing. CRC Press. London 2001, s. 34–60.
  • 13. Cheng-Lai A., Frishman W.H. Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease. Am. J. Ther. 2004; 11(3): 218–228, doi: 10.1097/00045391-200405000-00011.
  • 14. Halkin A., Stone G.W. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J. Interv. Cardiol. 2004; 17(5): 271–282, doi: 10.1111/j.1540-8183.2004.04040.x.
  • 15. Camenzind E., Steg P.G., Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115(11): 1440–1455, doi: 10.1161/CIRCULATIONAHA.106.666800.
  • 16. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 2006; 48(12): 2584–2591, doi: 10.1016/j.jacc.2006.10.026.
  • 17. Nordmann A.J., Briel M., Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J. 2006; 27(23): 2784–2814, doi: 10.1093/eurheartj/ehl282.
  • 18. Baim D.S., Mehran R., Kereiakes D.J., Gross T.P., Simons M., Malenka D., Kaplan A.V. Postmarket Surveillance for Drug-Eluting Coronary Stents. A Comprehensive Approach. Circulation 2006; 113: 891–897, doi: 10.1161/circulationaha.105.569657.
  • 19. Mauri L., Hsieh W.H., Massaro M., Ho K.K., D’Agostino R., Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 2007; 356(10): 1020–1029, doi: 10.1056/NEJMoa067731.
  • 20. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., Schömig A., Pfisterer M.E., Stone G.W., Leon M.B., Suarez de Lezo J., Goy J.J. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370(9591): 937–948, doi: 10.1016/S0140-6736(07)61444-5.
  • 21. Lagerqvist B., James S.K., Stenestrand U., Lindbäck J., Nilsson T., Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007; 356(10): 1009–1019, doi: 10.1056/NEJMoa067722.
  • 22. Bazell R. Millions face risk from drug-coated stents. NBC News. 2007. http://www.nbcnews.com/id/15816251/ns/health-heart_health/t/millions-facerisk-drug-coated-stents/#.XjoXTNThA1J [dostęp: 18.05.2020].
  • 23. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115(17): 2344–2351, doi: 10.1161/CIRCULATIONAHA.106.685313.
  • 24. Boam A. Update to FDA Statement on Coronary Drug-Eluting Stents. U.S. Department of Health and Human Services. Food and Drug Administration. 2008.
  • 25. Kotani J., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., Mintz G.S., Nagata S. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J. Am. Coll. Cardiol. 2006; 47(10): 2108–2111, doi: 10.1016/j.jacc.2005.11.092.
  • 26. Finn A.V., Joner M., Nakazawa G., Kolodgie F., Newell J., John M.C., Gold H.K., Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115(18): 2435–2441, doi: 10.1161/CIRCULATIONAHA.107.693739.
  • 27. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Jüni P., Sianos G., Hellige G., van Domburg R.T. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369(9562): 667–678, doi: 10.1016/S0140-6736(07)60314-6.
  • 28. Gada H., Kirtane A.J., Newman W., Sanz M., Hermiller J.B., Mahaffey K.W., Cutlip D.E., Sudhir K., Hou L., Koo K., Stone G.W. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc.Interv. 2013; 6(12): 1263–1266, doi: 10.1016/j.jcin.2013.07.009.
  • 29. Kedhi E., Joesoef K.S., McFadden E., Wassing J., van Mieghem C., Goedhart D., Smits P.C. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375(9710): 201–209, doi: 10.1016/S0140-6736(09)62127-9.
  • 30. Räber L., Magro M., Stefanini G.G., Kalesan B., van Domburg R.T., Onuma Y., Wenaweser P., Daemen J., Meier B., Jüni P., Serruys P.W., Windecker S. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125(9): 1110–1121, doi: /10.1161/CIRCULATIONAHA.111.058560.
  • 31. Sarno G., Lagerqvist B., Fröbert O., Nilsson J., Olivecrona G., Omerovic E., Saleh N., Venetzanos D., James S. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur. Heart J. 2012; 33(5): 606–613, doi: 10.1093/eurheartj/ehr479.
  • 32. Silber S., Windecker S., Vranckx P., Serruys P.W. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011; 377(9773): 1241–1247, doi: 10.1016/S0140-6736(11)60395-4.
  • 33. Tandjung K., Sen H., Lam M.K., Basalus M.W., Louwerenburg J.H., Stoel M.G., van Houwelingen K.G., de Man F., Linssen G.C.M., Saïd S.A.M., Nienhuis M.B. et al. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE Trial. J. Am. Coll. Cardiol. 2013; 61: 2406–2416, doi: 10.1016/j.jacc.2013.04.005.
  • 34. Taniwaki M., Stefanini G.G., Silber S., Richardt G., Vranckx P., Serruys P.W., Buszman P.E., Kelbaek H., Windecker SRESOLUTE All-Comers Investigators. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J. Am. Coll. Cardiol. 2014; 63(16): 1617–1625, doi: 10.1016/j.jacc.2013.12.036.
  • 35. Steg P.G., James S.K., Atar D., Badano L.P., Blömstrom-Lundqvist C., Borger M.A., Di Mario C., Dickstein K., Ducrocq G., Fernandez-Aviles F., Gershlick A.H. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur. Heart J. 2012; 33: 2569–2619, doi: 10.1093/eurheartj/ehs215.
  • 36. Muramatsu T., Onuma Y., Zhang Y.J., Bourantas C.V., Kharlamov A., Diletti R., Farooq V., Gogas B.D., Garg S., García-García H.M., Ozaki Y., Serruys P.W. Progress in treatment by percutaneous coronary intervention: the stent of the future. Rev. Esp. Cardiol. (Engl. Ed). 2013; 66(6): 483–496, doi: 10.1016/j.rec.2012.12.009.
  • 37. Thakkar A.S., Dave B.A. Revolution of drug-eluting coronary stents: an analysis of market leaders. Eur. Med. J. 2016; 1(4): 114–125.
  • 38. Smits P.C., Hofma S., Togni M., Vázquez N., Valdés M., Voudris V., Slagboom T., Goy J.J., Vuillomenet A., Serra A., Nouche R.T. et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013; 381 (9867): 651–660, doi: 10.1016/S0140-6736(12)61852-2.
  • 39. Zanchin C., Ueki Y., Zanchin T., Häner J., Otsuka T., Stortecky S., Koskinas K.C. , Siontis G.C.M., Praz F., Moschovitis A., Hunziker L. et al. Everolimus-eluting biodegradable polymer versus everolimus-eluting durable polymer stent for coronary revascularization in routine clinical practice. J. Am. Coll. Cardiol. Intv. 2019; 12(17): 1665–1675, doi: 10.1016/j.jcin.2019.04.046.40. Zanchin C., Yasushi U., Zanchin T. Everolimus-Eluting Biodegradable Po-lymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. JACC 2019; 12(17): 1665–1675, doi.org/10.1016/j.jcin.2019.04.046.
  • 41. Meredith I.T., Verheye S., Dubois C.L., Dens J., Fajadet J., Carrié D., Walsh S., Oldroyd K.G., Varenne O., El-Jack S., Moreno R. et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J. Am. Coll. Cardiol. 2012; 59(15): 1362–1370, doi: 10.1016/j.jacc.2011.12.016.
  • 42. Christiansen E.H., Jensen L.O., Thayssen P., Tilsted H.H., Krusell L.R., Hansen K.N., Kaltoft A.K., Maeng M., Kristensen S.D., Bøtker H.E, Terkelsen C.J. et al. For the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V Investigators. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013; 381: 661–669, doi: 10.1016/ S0140-6736(12)61962-X.
  • 43. Windecker S., Serruys P.W., Wandel S., Buszman P., Trznadel S., Linke A., Lenk K., Ischinger T., Klauss V., Eberli F., Corti R. et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008; 372 (9644): 1163–1173, doi: 10.1016/S0140-6736(08)61244-1.
  • 44. Bangalore S., Toklu B., Amoroso N., Fusaro M., Kumar S., Hannan E.L., Faxon D.P., Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013; 347: f6625, doi: 10.1136/bmj.f6625.
  • 45. Palmerini T., Biondi-Zoccai G., Della Riva D., Mariani A., Sabaté M., Smits P.C., Kaiser C., D’Ascenzo F., Frati G., Mancone M., Genereux P., Stone G.W. Clinical outcomes with bioabsorbable polymer-versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J. Am. Coll. Cardiol. 2014; 63(4): 299–307, doi: 10.1016/j.jacc.2013.09.061.
  • 46. De Scheerder I.K., Wilczek K.L., Verbeken E.V. et al. Biocompatibility of biodegradable and nonbiodegradable polymer-coated stents implanted in porcine peripheral arteries. Cardiovasc. Intervent. Radiol. 1995; 18: 227–232.
  • 47. van der Giessen W.J., Lincoff A.M., Schwartz R.S., van Beusekom H.M., Serruys P.W., Holmes Jr D.R., Ellis S.G., Topol E.J. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94(7): 1690–1697, doi: 10.1161/01.cir.94.7.1690.
  • 48. Chinn J.A., Sauter J.A., Phillips Jr R.E., Kao W.J., Anderson J.M., Hanson S.R., Ashton T.R. Blood and tissue compatibility of modified polyester: thrombosis, inflammation, and healing. J. Biomed. Mater Res. 1998; 39(1): 130–140, doi: 10.1002/(sici)1097-4636(19980101)39:1<130::aid-jbm15>3.0.co; 2-j.
  • 49. Liu T., Lin W., Huang L., Chen S., Yang M. Surface characteristics and hemocompatibility of PAN/PVDF blend membranes. Polym. Adv. Technol. 2005; 16(5): 413–419, doi: 10.1002/pat.592.
  • 50. Kolandaivelu K., Swaminathan R., Gibson W.J., Kolachalama V.B., Nguyen-Ehrenreich K.L., Giddings V.L., Coleman L., Wong G.K., Edelman E.R. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123(13): 1400–1409, doi: 10.1161/CIRCULATIONAHA.110.003210.
  • 51. Pepe M., Biondi-Zoccai G., Corcione N., Nestola P.L., Ferraro P., Morello A., Conte S., Prati F., Bianchi F.P, Bortone A.S., Giordano A. Comparative effectiveness and safety of polymer-free biolimus-eluting stent and durable polymer everolimus-eluting stent in all-comer patients who underwent percutaneous coronary interventions. Am. J. Cardiol. 2019; 124(2): 195–204, doi: 10.1016/j.amjcard.2019.04.015.
  • 52. Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa F., Jeppsson A., Jüni P., Kastrati A., Kolh P., Mauri L., Montalescot G. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 2018; 39(3): 213–260, doi: 10.1093/eurheartj/ehx419.
  • 53. Kufner S., Sorges J., Mehilli J., Cassese S., Repp J., Wiebe J., Lohaus R., Lahmann A., Rheude T., Ibrahim T., Massberg S. Randomized trial of polymer-free sirolimus- and probucol-eluting stents versus durable polymer zotarolimus-eluting stents: 5-year results of the ISAR-TEST-5 trial. JACC Cardiovasc. Interv. 2016; 9(8): 784–792, doi: 10.1016/j.jcin.2016.01.009.
  • 54. Yan B.P., Ajani A.E., New G., Duffy S.J., Farouque O., Shaw J., Sebastian M., Lew R., Brennan A., Andrianopoulos N., Reid C. et al. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry. Int. J. Cardiol. 2008; 130(3): 374–379, doi: 10.1016/j.ijcard.2008.06.046.
  • 55. Abe S., Sato A., Hoshi T., Maruta S. Drug-eluting versus bare-metal stents in large coronary arteries of patients with ST-segment elevation myocardial infarction: Findings from the ICAS registry. Journal of Cardiology 2014; 64(5): 377–383, doi: 10.1016/j.jjcc.2014.02.020.
  • 56. Pfisterer M., Brunner-La Rocca H.P., Rickenbacher P., Hunziker P., Mueller C., Nietlispach F., Leibundgut G., Bader F., Kaiser C. Long-term benefit–risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. European Heart Journal 2009; 30(1): 16–24, doi: 10.1093/eurheartj/ehn516.
  • 57. Brunner-La Rocca H.P., Kaiser C., Pfisterer M. Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). Eur. Heart J. 2007; 28(6): 719–725, doi: 10.1093/eurheartj/ehl490.
  • 58. Jeger R.V., Schneiter S., Kaiser C., Bonetti P.O., Brunner-La Rocca H., Handke M., Osswald S., Buser P.T., Pfisterer M.E. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology 2009; 112(1): 49–55, doi: 10.1159/000137699.
  • 59. Menozzi A., Solinas E., Ortolani P., Repetto A., Saia F., Piovaccari G., Manari A., Magagnini E., Vignali L., Bonizzoni E., Angelica P. et al. Twenty-four month clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. Eur. Heart J. 2009; 30(17): 2095–2101, doi: 10.1093/eurheartj/ehp224.
  • 60. Rodriguez-Granillo G.A., Valgimigli M., Garcia-Garcia H.M., Ong A.T.L., Aoki J., Mieghem C.A.G., Tsuchida K., Sianos G., McFadden E., van der Giessen W.J. One-year clinical outcome after coronary stenting of very small vessels using 2.25mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries. J. Invasive Cardiol. 2005; 17(8): 409–412, PMID: 16079445.
  • 61. Cortese B., Bertoletti A., De Matteis S., Danzi G.B., Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. Int. J. Cardiol. 2012; 161(2): 73–82, doi: 10.1016/j.ijcard.2011.04.016.
  • 62. Elezi S., Dibra A., Mehilli J.A., Pache J., Wessely R., Schömig A., Kastrati A. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J. Am. Coll. Cardiol. 2006; 48(7): 1304–1309, doi: 10.1016/j.jacc.2006.05.068.
  • 63. Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., Schömig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2006; 27(3): 260–266, doi: 10.1093/eurheartj/ehi721.
  • 64. Park K.H., Park S.W., Hong M.K., Kim Y.H., Lee B.K., Park D.W., Choi B.R., Kim M.J., Park K.M., Lee C.W., Cheong S.S. et al. Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions. Catheter Cardiovasc. Interv. 2006; 67(4): 589–594, doi: 10.1002/ccd.20700.
  • 65. Schunkert H., Harrell L., Palacios I.F. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J. Am. Coll. Cardiol. 1999; 34(1): 40–48, doi: 10.1016/s0735-1097(99)00181-3.
  • 66. Elezi S., Kastratie A., Neumann F.J., Hadamitzky M., Dirschinger J., Schömig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998; 98(18): 1875–1880, doi: 10.1161/01.cir.98.18.1875.
  • 67. Biondi-Zoccai G., Moretti C., Abbate A., Sheiban I. Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovasc. Revasc. Med. 2010; 11(3): 189–198, doi: 10.1016/j.carrev.2009.04.007.
  • 68. Akiyama T., Moussa I., Reimers B., Ferraro M., Kobayashi Y., Blengino S., Di Francesco L., Finci L., Di Mario C., Colombo A. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J. Am. Coll. Cardiol. 1998; 32: 1610–1618, doi: 10.1016/S0735-1097(98)00444-6.
  • 69. Agostoni P., Biondi-Zoccai G.G., Gasparini G.L., Anselmi M., Morando G., Turri M., Abbate A., McFadden E.P., Vassanelli C., Zardini P., Colombo A., Serruys P.W. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur. Heart J. 2005; 26(9): 881–889, doi: 10.1093/eurheartj/ehi116.
  • 70. van der Heijden L.C., Kok M.M., Danse P.W., Schramm A.R., Hartmann M., Löwik M.M., Linssen G.C.M., Stoel M.G., Doggen C.J.M., von Birgelen C. Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial. Am. Heart J. 2016; 176: 28–35, doi: 10.1016/j.ahj.2016.02.020.
  • 71. Claessen B.E., Smits P.C., Kereiakes D.J., Parise H., Fahy M., Kedhi E., Serruys P.W., Lansky A.J., Cristea E., Sudhir K., Sood P. et al. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents: Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC: Cardiovascular Interventions 2011; 4(11): 1209–1215, doi: 10.1016/j.jcin.2011.07.016.
  • 72. Buiten R.A., Ploumen E.H., Zocca P., Doggen C.J.M., van der Heijden L.C., Kok M.M., Danse P.W., Schotborgh C.E., Scholte M., de Man F.H., Linssen G.C.M., von Birgelen C. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial. JAMA Cardiol. 2019; 4(7): 659–669, doi: 10.1001/jamacardio.2019.1776.
  • 73. Iglesias J.F., Muller O., Heg D., Roffi M., Kurz D.J., Moarof I., Weilenmann D., Kaiser C., Tapponnier M., Stortecky S., Losdat S. et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet 2019; 394(10205): 1243–1253, doi: 10.1016/S0140-6736(19)31877-x.
  • 74. Kandzari D.E., Koolen J.J., Doros G., Massaro J.J., Garcia-Garcia H.M., Bennett J., Roguin A., Gharib E.G., Cutlip D.E., Waksman R. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents JACC 2018; 72(25): 3287–3297, doi: 10.1016/j.jacc.2018.09.019.
  • 75. Saito S., Toelg R., Witzenbichler B., Haude M., Masotti M., Salmeron R. BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months. EuroIntervention 2019; 15(11): 1006–1013, doi: 10.4244/eij-d-18-01214.
  • 76. Iglesias J.F., Muller O., Heg D., Roffi M., Kurz D.J., Moarof I. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet 2019; 394(10205): 1243–1253, doi: 10.1016/s0140-6736(19)31877-x.
  • 77. Park D.W., Kim Y.H., Yun S.C., Ahn J.M., Lee J.Y., Kim W.J., Kang S.J., Lee S.W., Lee C.W., Park S.W., Park S.J. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. European Heart Journal 2013; 34(22): 1662–1669, doi: 10.1093/eurheartj/eht048.
  • 78. Kawamoto H., Panoulas V.F., Sato K., Miyazaki T., Naganuma T., Sticchi A. et al. Impact of strut width in periprocedural myocardial infarction: a propensity-matched comparison between bioresorbable scaffolds and the first-generation sirolimus-eluting Stent. JACC: Cardiovasc. Interv. 2015; 8(7): 900–909, doi: 10.1016/j.jcin.2015.02.011.
  • 79. Koskinas K.C., Chatzizisis Y.S., Antoniadis A.P., Giannoglou G.D. Role of endothelial shear stress in stent restenosis and thrombosis pathophysiologic mechanisms and implications for clinical translation. J. Am. College Cardiol. 2012; 59(15): 1337–1349, doi: 10.1016/j.jacc.2011.10.903.
  • 80. Kitabata H., Kubo T., Komukai K. et al. Effect of strut thickness on neointimal atherosclerotic change over an extended follow-up period. Am. Heart J. 2012; 163(4): 608–616, doi: 10.1016/j.ahj.2012.01.007.
  • 81. Ng J., Bourantas C.V., Torii R., Ang H.Y., Tenekecioglu E., Serruys, P.W.Foin N. Local hemodynamic forces after stenting. Implications on restenosis and thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2017; 37: 2231–2242, doi: 10.1161/ATVBAHA.117.309728.
  • 82. Wasilewski J., Osadnik T., Peryt−Stawiarska S., Poloński L. The role of haemodynamic factors in the development of in-stent restenosis. Polish Heart J. 2012; 70(11): 1194–1198. https://www.mp.pl/kardiologiapolska/en/node/11764/pdf.
  • 83. Fukumoto Y., Hiro T., Fujii T., Hashimoto G., Fujimura T., Yamada J., Okamura T., Matsuzaki M. Localized elevation of shear stress is related to coronary plaque rupture. A 3-dimensional intravascular ultrasound study with in-vivo color mapping of shear stress distribution. J. Am. Coll. Cardiol. 2008; 51(6): 645–650, doi: 10.1016/j.jacc.2007.10.030.
  • 84. Serruys P.W., Chevalier B., Sotomi Y., Cequier A., Carrié D., Piek J.J., Van Boven A.J., Dominici M., Dudek D., McClean D., Helqvist S., Haude M. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II). Lancet 2016; 388(10059): 2479–2491, doi: 10.1016/S0140-6736(16)32050-5.
  • 85. Kereiakes D.J., Ellis S.G., Metzger C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S.O., Popma J.J. et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: The ABSORB III Trial. J. Am. Coll. Cardiol. 2017; 70(23): 2852–2862, doi: 10.1016/j.jacc.2017.10.010.
  • 86. Palmerini T., Benedetto U., Biondi-Zoccai G., Riva D.D., Bacchi-Reggiani L., Smits P.C., Vlachojannis G.J., Jensen L.O., Christiansen E.H., Berencsi K., Valgimigli M. et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents Evidence From a Comprehensive Network Meta-Analysis. J. Am. Coll. Cardiol. 2015; 65: 2496–2507, doi: 10.1016/j.jacc.2015.04.017.
  • 87. Savvoulidis P., Perlman G., Bagur R. The EluNIRTM ridaforolimus elu-ting coronary stent system. Expert Rev. Med. Devices. 2019; 16(1): 71–76, doi: 10.1080/17434440.2018.1549986.
  • 88. Rapetto C., Leoncini M. Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives. J. Thorac. Dis. 2017; 9(Suppl 9): 903–913, doi: 10.21037/jtd.2017.06.34.
  • 89. Verheye S., Ormiston J.A., Stewart J., Webster M., Sanidas E., Costa R., Costa Jr J.R., Chamie D., Abizaid A.S., Pinto I., Morrison L. et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc. Interv. 2014; 7(1): 89–99, doi: 10.1016/j.jcin.2013.07.007.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-540454cf-b4e5-4b4f-8c2b-f7e014a8f890
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.